Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $1.67 in the prior trading day, Cardiol Therapeutics Inc (NASDAQ: CRDL) closed at $1.77, up 5.99%. In other words, the price has increased by $5.99 from its previous closing price. On the day, 0.57 million shares were traded. CRDL stock price reached its highest trading level at $1.78 during the session, while it also had its lowest trading level at $1.55.
Ratios:
Our goal is to gain a better understanding of CRDL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.36 and its Current Ratio is at 4.36. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDL now has a Market Capitalization of 122456384 and an Enterprise Value of 86078176.
Stock Price History:
Over the past 52 weeks, CRDL has reached a high of $2.17, while it has fallen to a 52-week low of $0.51. The 50-Day Moving Average of the stock is 9.41%, while the 200-Day Moving Average is calculated to be 60.22%.
Shares Statistics:
The stock has traded on average 397.20K shares per day over the past 3-months and 233780 shares per day over the last 10 days, according to various share statistics. A total of 65.35M shares are outstanding, with a floating share count of 65.04M. Insiders hold about 4.73% of the company’s shares, while institutions hold 10.28% stake in the company. Shares short for CRDL as of 1711584000 were 326642 with a Short Ratio of 0.82, compared to 1709164800 on 361076. Therefore, it implies a Short% of Shares Outstanding of 326642 and a Short% of Float of 0.52.
Earnings Estimates
The performance of Cardiol Therapeutics Inc (CRDL) in the stock market is under the watchful eye of CLDL analysts actively contributing to its current rating.The consensus estimate for the next quarter is $4.35, with high estimates of $226.78 and low estimates of $16.92.
